Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10 results about "Lipid absorption" patented technology

Lipid Absorption. Lipids within the digestive system will tend to hydrophobically aggregate to form large fat globules. Bile salts, secreted from the gall bladder, emulsify these fat globules and break them up into smaller droplets. Hydrolytic enzymes called lipases then digest the fats into their component parts.

Application of ganoderic acid A in preparation of product for preventing and / or treating non-alcoholic fatty liver disease

The invention discloses an application of ganoderic acid A in preparation of a product for preventing and / or treating a non-alcoholic fatty liver disease. The ganoderic acid A can regulate bile acid reabsorption of C57BL / 6J mice induced by high fat diet and reduce absorption of triglyceride and cholesterol. The ganoderic acid A can also enhance expression of a key enzyme cholesterol 7alpha-hydroxylase gene for liver cholesterol decomposition, so that liver cholesterol is promoted to be converted into bile acid, and accumulation of liver cholesterol is relieved. The ganoderic acid A has remarkable prevention and improvement effects on the non-alcoholic fatty liver disease induced by high fat diet by regulating bile acid metabolism, inhibiting lipid absorption and relieving liver lipid accumulation. Therefore, the ganoderic acid A can be used as a health-care product, a functional product or a medicine for preventing and treating the non-alcoholic fatty liver disease.
Owner:PEKING UNIV +1

Use of ganoderic acid a in preparation of product for preventing and / or treating non-alcoholic fatty liver disease

PCT designated stageWO2026007239A1Organic active ingredientsDigestive systemMetabolic SuppressionNonalcoholic fatty liver disease
Use of ganoderic acid A in the preparation of a product for preventing and / or treating non-alcoholic fatty liver disease. Ganoderic acid A can regulate bile acid reabsorption in C57BL / 6J mice induced by a high-fat diet, and reduce the absorption of triglycerides and cholesterol. Ganoderic acid A can also enhance the expression of the gene of cholesterol 7α-hydroxylase, a key enzyme for liver cholesterol decomposition, thereby promoting the conversion of liver cholesterol into bile acid, and alleviating the accumulation of liver cholesterol. Ganoderic acid A has a significant preventive and ameliorative effect on non-alcoholic fatty liver disease induced by a high-fat diet by means of regulating bile acid metabolism, inhibiting lipid absorption, and reducing liver lipid accumulation. Therefore, ganoderic acid A can be used as a health care product, a functional product, or a drug for preventing and treating non-alcoholic fatty liver disease.
Owner:PEKING UNIV +1

A fat composition, method of making and use thereof

The present application belongs to the field of food oil and fat, and particularly relates to an oil and fat composition, a preparation method and use thereof. The oil and fat composition comprises sterol laurate and modified palm oil, wherein the mass ratio of the sterol laurate and the modified palm oil is (0.5-3):100. The sterol is subjected to esterification with lauric acid under vacuum to obtain a sterol laurate esterification product; the enzyme-modified palm oil is stirred and mixed with the sterol laurate esterification product to obtain the oil and fat additive suitable for poultry daily ration. The present application firstly utilizes the oil and fat composition prepared by compounding the enzyme-modified palm oil and the sterol laurate esterification product as the oil and fat for poultry daily ration. The oil and fat composition reduces the feed-meat ratio of broiler, improves the lipid absorption rate, and improves the absorption of calcium and phosphorus by poultry.
Owner:JINAN UNIVERSITY

A yolk-derived peptide for lowering blood lipids, a preparation method, a pharmaceutical composition and use thereof

PendingCN122301989AYolkPancrelipase
This invention relates to the pharmaceutical field, specifically to an egg yolk-derived peptide for lowering blood lipids, its preparation method, pharmaceutical composition, and uses. This invention discovers an egg yolk-derived peptide obtained by enzymatic hydrolysis, digestion, separation, and purification of defatted egg yolk powder. Its amino acid sequence is shown in SEQ ID NO.1. This peptide possesses high potential activity for lowering blood lipids. In vitro pancreatic lipase inhibition experiments and hyperlipidemic cell model experiments demonstrate that the egg yolk-derived peptide of this invention can affect lipid absorption and metabolism, thereby alleviating lipid metabolism disorders and lipid accumulation, ultimately reducing TC and TG levels.
Owner:HUAZHONG AGRI UNIV

Probiotic dietary fiber composite composition for body weight management and preparation method thereof

The invention discloses a probiotic dietary fiber composite composition for body weight management and a preparation method thereof in the field of functional food. The composition comprises a composite system composed of probiotics, prebiotics, a dietary fiber matrix and two special inorganic modified carriers. The two carriers are respectively a mesoporous silica magnesium-aluminum layered double hydroxide hybrid nano-carrier and a zinc-doped calcium phosphate silica core-shell nano-particle. During preparation, firstly, the probiotics are loaded on the hybrid nano-carrier and protected, then the hybrid nano-carrier, the core-shell nanoparticles, fructo-oligosaccharide and other components are compounded into a gel matrix constructed by cellulose nanofibers and carrageenan together, and a final product is obtained through homogenization and freeze drying. Through the synergistic effect of the two carriers, the targeted survival rate of the probiotics in the intestinal tract is remarkably improved, and the multiple effects of adsorbing grease, delaying glycolipid absorption and adjusting intestinal flora are achieved at the same time, so that safe and effective weight management is achieved.
Owner:HENAN WOBON BEVERAGE CO LTD

Composite substitutional tea bag with function of reducing blood pressure and blood fat and preparation method of composite substitutional tea bag

The invention discloses a compound substitutional tea bag with blood pressure and blood fat reducing functions and a preparation method thereof, and the compound substitutional tea bag is used for synergistically assisting in reducing blood pressure from different mechanisms through the vasodilation effect of gastrodia elata and radix puerariae, the cardiovascular protection effect of chrysanthemum and the diuretic effect of corn stigma; the hawthorn, the semen cassiae, the lotus leaves and the lucid ganoderma are used for regulating and controlling lipid absorption, synthesis and excretion in multiple links, so that the effect of assisting in reducing blood fat is jointly exerted; besides, the flavors of all the raw materials are ingeniously balanced, the sour and refreshing taste of hawthorn, the faint scent of chrysanthemum and the sweet and light taste of corn stigma effectively neutralize the slight bitter taste of semen cassiae and lotus leaves, and due to the fact that gastrodia elata, radix puerariae and lucid ganoderma do not have obvious bad flavors, final tea soup is clear in color and luster, mellow in taste, free of strong bitter taste of traditional Chinese medicine and easy to accept by consumers; the long-term drinking compliance is ensured.
Owner:JIUXIN CHINESE MEDICINE GRP CO LTD

A method for assessing lipid absorption by re-esterification assay and its application

This invention discloses a method for assessing lipid reesterification, belonging to the field of biochemistry. Based on radioisotope-labeled assisted liquid scintillation counting technology, this invention provides a method for evaluating the reesterification of functional lipids. For the reaction of fatty acids with coenzyme A to form acyl-CoA, coenzyme A is labeled with a radioisotope, and the reesterification rate of fatty acids is quantified by calculating the isotope recovery rate in the product. For the reaction of sterols with acyl-CoA to form sterol fatty acid esters, sterols and acyl-CoA are labeled with two different isotopes respectively. The reduction of acyl-CoA in the reactants and the formation of sterol fatty acid esters in the product are characterized by detecting the intensity of the two isotopes simultaneously carried in the product, thus quantifying the reesterification rate of sterols. This invention uses labeled coenzyme A as an evaluator for the metabolic process, precisely locating the lipid metabolic pathway to the esterification reaction involving coenzyme A, eliminating the influence of unknown metabolic pathways.
Owner:ZHEJIANG UNIV

A postbiotic and its use in modulating the direction of lipid metabolism

The present application relates to a probiotic and its application in regulating the direction of lipid metabolism. Specifically, the present application relates to the use of the probiotic in the preparation of a medicine or food. The present application also relates to a method for regulating the body weight of a subject, and a method for inhibiting or reducing the absorption of lipids in the gastrointestinal tract of a subject.
Owner:BY HEALTH CO LTD